Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1420042
European Journal of Endocrinology, Vol 142, Issue 1, 42-46
Copyright © 2000 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radetti, G
Right arrow Articles by Adami, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radetti, G
Right arrow Articles by Adami, S
Clinical Studies

A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization

G Radetti, F Buzi, C Paganini, C Martelli, and S Adami

Department of Pediatrics, Regional Hospital of Bolzano, Italy. G.Radetti@ntt.it

To evaluate the effects of two regimens of recombinant human GH (rhGH) on growth, bone growth and bone mineralization in GH deficient children, we studied two groups (A and B), each including 16 GH deficient children matched for sex, age, body mass index, height, height velocity and bone age/chronological age ratio (BA/CA). Group A was treated with a weekly rhGH dose of 1IU/kg and group B with 0.5IU/kg. After four years of therapy, we evaluated the auxological outcome, bone morphometry (metacarpal index: MI) and bone mineralization by quantitative roentgen microdensitometry at the middle region of the II metacarpal and ultra-distal radius. Height increased significantly in both groups, being significantly higher in group A after four years of therapy, while BA/CA remained similar in the two groups. Bone growth (measured by the MI), and bone mineral density at the metacarpal (mostly trabecular bone) and at the ultra-distal radial (mostly cortical bone) site did not differ in the two groups, nor did these three parameters differ from normal controls. In conclusion, after four years a greater height gain was achieved by the higher dose of rhGH compared with the conventional dose, but there were no differences in bone growth and mineralization.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers
Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition
Endocr. Rev., April 1, 2006; 27(2): 101 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Radetti, G. D'Addato, D. Gatti, M. Bozzola, and S. Adami
Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
Eur. J. Endocrinol., March 1, 2006; 154(3): 479 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Endocr. Rev., February 1, 2005; 26(1): 114 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Cohen, G. M. Bright, A. D. Rogol, A.-M. Kappelgaard, and R. G. Rosenfeld
Effects of Dose and Gender on the Growth and Growth Factor Response to GH in GH-Deficient Children: Implications for Efficacy and Safety
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 90 - 98.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 European Society of Endocrinology.